Matthew Pauls Savara Inc (SVRA) insider trading activity

Matthew Pauls is CHIEF EXECUTIVE OFFICER of Savara Inc. Currently has a direct ownership of 1.19 Million shares of SVRA, which is worth approximately $5.16 Million. The most recent transaction as insider was on Dec 16, 2025, when has been sold 128,995 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.19M

22.67% 3M change

22.67% 12M change

Total Value Held $5.16 Million

Matthew Pauls Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2025	SELL Bona fide gift	-	128,995 Reduced 9.79%	1,188,050 Common Stock
Dec 14 2025	SELL Payment of exercise price or tax liability	$1,354,278 $6.92 p/Share	195,705 Reduced 12.94%	1,317,045 Common Stock
Dec 10 2025	SELL Bona fide gift	-	23,629 Reduced 1.54%	1,512,750 Common Stock
Dec 16 2024	SELL Open market or private sale	$181,063 $3.31 p/Share	54,702 Reduced 3.44%	1,536,379 Common Stock
Dec 13 2024	SELL Payment of exercise price or tax liability	$297,223 $3.21 p/Share	92,593 Reduced 5.5%	1,591,081 Common Stock
Dec 12 2024	BUY Grant, award, or other acquisition	-	400,000 Added 19.2%	1,683,674 Common Stock
Dec 28 2023	SELL Bona fide gift	-	19,000 Reduced 1.46%	1,283,674 Common Stock

Dec 28 2023	SELL Open market or private sale	$395,640 $4.71 p/Share	84,000 Reduced 6.06%	1,302,674 Common Stock
Dec 14 2023	SELL Payment of exercise price or tax liability	$488,076 $4.45 p/Share	109,680 Reduced 10.48%	936,674 Common Stock
Dec 14 2023	BUY Grant, award, or other acquisition	-	450,000 Added 24.5%	1,386,674 Common Stock
Dec 13 2022	BUY Grant, award, or other acquisition	-	325,000 Added 23.7%	1,046,354 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$77,274 $1.24 p/Share	62,318 Reduced 7.95%	721,354 Common Stock
Dec 14 2021	BUY Grant, award, or other acquisition	-	400,000 Added 33.79%	783,672 Common Stock
Dec 08 2021	BUY Open market or private purchase	$6,890 $1.06 p/Share	6,500 Added 1.67%	383,672 Common Stock
Dec 02 2021	BUY Open market or private purchase	$11,000 $1.1 p/Share	10,000 Added 2.58%	377,172 Common Stock
Nov 19 2021	BUY Open market or private purchase	$13,244 $1.09 p/Share	12,150 Added 3.2%	367,172 Common Stock
Nov 18 2021	BUY Open market or private purchase	$11,000 $1.1 p/Share	10,000 Added 2.74%	355,022 Common Stock
Aug 18 2021	BUY Open market or private purchase	$14,161 $1.19 p/Share	11,900 Added 3.33%	345,022 Common Stock
Aug 17 2021	BUY Open market or private purchase	$17,700 $1.18 p/Share	15,000 Added 4.31%	333,122 Common Stock
May 21 2021	BUY Open market or private purchase	$16,300 $1.63 p/Share	10,000 Added 3.05%	318,122 Common Stock
Apr 19 2021	BUY Open market or private purchase	$49,868 $1.82 p/Share	27,400 Added 8.17%	308,122 Common Stock
Mar 22 2021	BUY Open market or private purchase	$49,887 $2.07 p/Share	24,100 Added 7.91%	280,722 Common Stock
Feb 22 2021	BUY Open market or private purchase	$49,938 $1.74 p/Share	28,700 Added 10.06%	256,622 Common Stock

Also insider at

SLNO

SOLENO THERAPEUTICS INC Healthcare

CHRO

Chromocell Therapeutics Corp

Director

Matthew Pauls

CHIEF EXECUTIVE OFFICER

Austin, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SVRA shares.

Notify only if

Value

Insider Trading

Get notified when an Savara Inc insider buys or sells SVRA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Savara Inc

Track Activities on SVRA

Account